Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilucoplan Auto-Injector in Generalized Myasthenia Gravis
NCT06471361Phase 3Completed
- Sponsor
- UCB
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Cyclic Peptides
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of zilucoplan in myasthenia gravis (MG), sponsored by UCB. Primary endpoint: Percentage of Effective Self-administrations (SA) of Zilucoplan (ZLP) Using the Zilucoplan-auto-injector (ZLP-AI) at 14 days. Started Aug 2024; status: completed.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06471361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471361.